{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:49:08Z","timestamp":1784306948228,"version":"3.55.0"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective treatment options are limited for elderly patients with acute myeloid leukemia (AML). A prospective phase II study was conducted to investigate the safety and efficacy of pegylated liposomal doxorubicin (PLD) combined with low-dose cytarabine (LDAC) and granulocyte colony-stimulating factor (G-CSF) in newly diagnosed older and unfit AML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-two patients were enrolled and deemed evaluable. The study included one cycle of induction and four cycles of consolidation, followed by maintenance therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of enrolled patients was 71.5 years (range, 63 to 82 years), and 16 patients (72.7%) were over 70 years of age. The overall response rate (ORR) was 77.3% (n\u2009=\u200917) and the complete remission (CR)\/complete remission with incomplete recovery (CRi) rate was 63.6% (n\u2009=\u200914) after the first induction cycle. With a median follow-up of 12.4 months, eight patients (57.1%) relapsed, with a median time to relapse of 12.3 months. The median duration of response (DOR) was 11.9 months (95% CI, 6.4 to NA months), the median overall survival (OS) was 15 months (95% CI, 8.4 to 21.6 months), and the median progression-free survival (PFS) was 7.5 months (95% CI, 4.6 to 15.1 months). Common grade 3 or greater adverse events included febrile neutropenia (77.8%) and infection (63.6%), with pneumonia being the most common (10, 45.5%). There was one death (4.5%) within 30 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of PLD, LDAC, and G-CSF is well-tolerated and exhibits high rates of CR\/CRi and low early mortality, providing an attractive treatment option for newly diagnosed elderly and unfit AML patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15330338241312436","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T21:56:22Z","timestamp":1743112582000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8060-6388","authenticated-orcid":false,"given":"Bingqing","family":"Luo","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2662-5310","authenticated-orcid":false,"given":"Xiaoyan","family":"Tan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4680-877X","authenticated-orcid":false,"given":"Yanfang","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9751","authenticated-orcid":false,"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9283-0555","authenticated-orcid":false,"given":"Hanqing","family":"Zeng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-1763","authenticated-orcid":false,"given":"Hongbo","family":"Xiao","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4734-6431","authenticated-orcid":false,"given":"Shifeng","family":"Lou","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-409X","authenticated-orcid":false,"given":"Kang","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005"},{"issue":"12","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29319","article-title":"Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis","volume":"121","author":"Percival ME","year":"2015","unstructured":"Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis. Cancer. 2015;121(12):2004-2012.","journal-title":"Cancer"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361410"},{"issue":"1","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.26395","article-title":"Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy","volume":"97","author":"Sasaki K","year":"2022","unstructured":"Sasaki K, Kadia T, Begna K, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97(1):68-78.","journal-title":"Am J Hematol"},{"issue":"3","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret H","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-299.","journal-title":"Blood"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"issue":"2","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea DA","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208-217.","journal-title":"Am J Hematol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2016.10.003"},{"issue":"2","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.24273","article-title":"Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03","volume":"60","author":"Escherich G","year":"2013","unstructured":"Escherich G, Zimmermann M, Janka-Schaub G. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. Pediatr Blood Cancer. 2013;60(2):254-257.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives","volume":"27","author":"Liu P","year":"2022","unstructured":"Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022;27(4):1372.","journal-title":"Molecules"},{"key":"e_1_3_3_12_2","first-page":"100374","article-title":"A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML","volume":"19","author":"Jonas BA","year":"2023","unstructured":"Jonas BA, Potter LA, Galkin M, Tuscano JM. A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML. Leuk Res Rep. 2023;19:100374.","journal-title":"Leuk Res Rep"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000811"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh097"},{"issue":"1","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: A multicentric French cohort","volume":"5","author":"Chiche E","year":"2021","unstructured":"Chiche E, Rahm\u00e9 R, Bertoli S, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: A multicentric French cohort. Blood Adv. 2021;5(1):176-184.","journal-title":"Blood Adv"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-540971"},{"issue":"16","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","volume":"18","author":"Murphy T","year":"2017","unstructured":"Murphy T, Yee KWL. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2017;18(16):1765-1780.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"e_1_3_3_19_2","first-page":"826","article-title":"Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro","volume":"4","author":"Tafuri A","year":"1990","unstructured":"Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia. 1990;4(12):826-834.","journal-title":"Leukemia"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-46"},{"issue":"5","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jgo.2015.03.003","article-title":"Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH scale","volume":"6","author":"Bonanad S","year":"2015","unstructured":"Bonanad S, De la Rubia J, Gironella M, et al. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH scale. J Geriatr Oncol. 2015;6(5):353-361.","journal-title":"J Geriatr Oncol"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29090491"},{"issue":"11","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older patients with acute myeloid leukemia deserve individualized treatment","volume":"24","author":"de Leeuw DC","year":"2022","unstructured":"de Leeuw DC, Ossenkoppele GJ, Janssen J. Older patients with acute myeloid leukemia deserve individualized treatment. Curr Oncol Rep. 2022;24(11):1387-1400.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/cancers16061082","article-title":"Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia","volume":"16","author":"Chen TT","year":"2024","unstructured":"Chen TT, Lin CC, Lo WJ, et al. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia. Cancers (Basel). 2024;16(6):1082.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11912-020-00987-8","article-title":"Access to therapy for acute myeloid leukemia in the developing world: Barriers and solutions","volume":"22","author":"Meillon-Garcia LA","year":"2020","unstructured":"Meillon-Garcia LA, Demichelis-Gomez R. Access to therapy for acute myeloid leukemia in the developing world: Barriers and solutions. Curr Oncol Rep. 2020;22(12):125.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2021-147805","article-title":"AGILE: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation","volume":"138","author":"Montesinos P","year":"2021","unstructured":"Montesinos P, Recher C, Vives S, et al. AGILE: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Blood. 2021;138(supplement 1):697-697.","journal-title":"Blood"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00494-0"},{"issue":"17","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang ES","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845-1857.","journal-title":"Blood"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"issue":"15","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase ib\/II study","volume":"37","author":"Wei AH","year":"2019","unstructured":"Wei AH, Strickland Jr SA, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase ib\/II study. J Clin Oncol. 2019;37(15):1277-1284.","journal-title":"J Clin Oncol"},{"issue":"22","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian H","year":"2010","unstructured":"Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422\u20134429.","journal-title":"Blood"},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"619085","DOI":"10.3389\/fonc.2020.619085","article-title":"Maintenance therapy in AML","volume":"10","author":"Reville PK","year":"2020","unstructured":"Reville PK, Kadia TM. Maintenance therapy in AML. Front Oncol. 2020;10:619085.","journal-title":"Front Oncol"},{"issue":"5","key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom medical research council AML11 trial","volume":"98","author":"Goldstone AH","year":"2001","unstructured":"Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom medical research council AML11 trial. Blood. 2001;98(5):1302-1311.","journal-title":"Blood"},{"issue":"13","key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls G","year":"2019","unstructured":"Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133(13):1457-1464.","journal-title":"Blood"},{"issue":"26","key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei AH","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526-2537.","journal-title":"N Engl J Med"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338241312436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338241312436","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338241312436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:16:03Z","timestamp":1777702563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338241312436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":37,"alternative-id":["10.1177\/15330338241312436"],"URL":"https:\/\/doi.org\/10.1177\/15330338241312436","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338241312436\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338241312436\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338241312436\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338241312436\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338241312436\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338241312436\/v2\/review1","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"15330338241312436"}}